6533b7d2fe1ef96bd125e13a

RESEARCH PRODUCT

Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions

F. FerlitoDomenico MirabellaEttore DinotoDavid PakelianiFelice PecoraroGuido Bajardi

subject

MaleTime Factorsmedicine.medical_treatmentConstriction Pathologic030204 cardiovascular system & hematologySeverity of Illness IndexSettore MED/22 - Chirurgia Vascolare030218 nuclear medicine & medical imaging0302 clinical medicineRestenosisCoated Materials BiocompatibleIschemiaRecurrenceMedicineProspective StudiesAged 80 and overEndovascularCritical limb ischemiaGeneral MedicineEquipment DesignLimb SalvagePlaque AtheroscleroticTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicineVascular Access Devicesmedicine.medical_specialtyPaclitaxelPopliteal arteryCritical IllnessDrug eluting balloonAmputation Surgical03 medical and health sciencesPeripheral Arterial Diseasemedicine.arteryAngioplastyHumansVascular PatencyAgedbusiness.industryAngioplastyCardiovascular AgentsCritical limb ischemiaPerioperativeIntermittent Claudicationmedicine.diseasePopliteal arterySurgeryStenosisAmputationSurgerybusinessClaudicationAngioplasty Balloon

description

Purpose: Reporting outcomes with a new generation paclitaxel eluting balloon (Luminor®; iVascular, Vascular, S.L.U., Barcelona, Spain) in the popliteal district. Endovascular treatment of popliteal artery atherosclerotic disease is still debated without definitive evidences. Methods: From January to June 2019, patients’ data presenting popliteal artery atherosclerotic diseases and treated with the Luminor® (iVascular) drug eluting balloon (DEB) were prospectively collected. Critical limb ischemia (CLI) or severe claudication associated with popliteal artery stenosis >50% were the inclusion criteria. Measured outcomes were technical success, early and late results; including mortality, morbidity, symptoms recurrence, amputation, ankle-brachial index (ABI), survival, primary patency, secondary patency, freedom from restenosis. Median follow-up was 22.43 ± 4 (mean:21.58; IQR:20-24) months. Results: Of the 33 included patients, 28 (85%) were diagnosed with CLI, with a mean preoperative run-off score of 5.39 (r:0-10; SD:3) and a chronic popliteal occlusion in 21 (64%). Technical success was achieved in all cases. Perioperative mortality was observed in 1 (3%) patient and perioperative complications in 2 (6%). During the follow-up were reported 2 symptoms recurrence; a significant ABI increase (0.57; IQR:0.41-0.47 vs. 0.69; IQR:0.50-0.67; P < 0.01); 1 (3%) major and 2 (6%) minor amputations. Estimated 24 months survival, primary patency, secondary patency, and freedom from restenosis were 97%, 96.9%, 100%, and 93.8% respectively. Conclusions: In this prospective study, the use of the Luminor® (iVascular) was safe and effective in addressing atherosclerotic popliteal artery lesions. Larger studies with longer term-outcomes are required to assess the durability of this device in the popliteal artery.

yearjournalcountryeditionlanguage
2021-02-12
10.1016/j.avsg.2021.04.015http://hdl.handle.net/10447/514438